The prognostic value of CD44 isoform expression in endometrial cancer

Tempfer, Clemens; Haeusler, G.; Kaider, Alexandra; Hefler, Lukas; Hanzal, Engelbert; Reinthaller, Alexander; Breitenecker, G.; Kainz, Christian

doi:10.1038/bjc.1998.188

Cited by 21 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A relation was also found between TIMP-2 downregulation in G3 EC compared to G1 and 2 but without difference between these two latter grades. These results are in agreement with those using microarray gene expression demonstrating that TIMP-2 isdownregulated in high grade tumours There are limited and controversial reports on CD44 expression in EC [47,48]. Our PCA analysis supports the contribution of CD44 in EC.…”

Section: Discussionsupporting

confidence: 92%

Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer

Laas

Ballester

Cortez

et al. 2017

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Considerable heterogeneity exists in outcomes of early endometrial cancer (EC) according to the type but also the histological grading. Our goal was to describe the immunohistochemical profiles of type I EC according to grades and type II EC, to identify groups of interacting proteins using principal component analysis (PCA) and unsupervised clustering. We studied 13 immunohistochemical markers (steroid receptors, pro/anti-apoptotic proteins, metalloproteinases (MMP) and tissue inhibitor of metalloproteinase (TIMP), and CD44 isoforms known for their role in endometrial pathology. Co-expressed proteins associated with the type, grade and outcome of EC were determined by PCA and unsupervised clustering. PCA identified three functional groups of proteins from 43 tissue samples (38 type I and 5 type II EC): the first was characterized by p53 expression; the second by MMPs, bcl-2, PR B and CD44v6; and the third by ER alpha, PR A, TIMP-2 and CD44v3. Unsupervised clustering found two main clusters of proteins, with both type I grade 3 and type II EC exhibiting the same cluster profile. PCA and unsupervised clustering of immunohistochemical markers in EC contribute to a better comprehension and classification of the disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer

Laas

Ballester

Cortez

et al. 2017

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…HA expression resembles this pattern [25, 37]. However, some data indicate less intensive expression of the CD44 in cancer cells [27, 29, 30, 33]. …”

Section: Discussionmentioning

confidence: 89%

CD44 expression in curettage and postoperative specimens of endometrial cancer

Wojciechowski

Krawczyk

Śmigielski

et al. 2014

Arch Gynecol Obstet

View full text Add to dashboard Cite

BackgroundAdhesive molecules like CD44 are well defined key players in the metastatic cascade in many cancers, including endometrial cancer. They could play a role of markers of invasion, metastasis and prognostic factors.Aim of the studyThe aim of the study is to assess a possible role of the CD44 as a marker of invasion in endometrial cancer, both at the moment of preoperative workup and final staging.Materials and methodsAvailable for analysis were archival specimens of 51 patients who had underwent curettage and surgery between 2002 and 2007. An immunohistochemical study for CD44 expression was performed in curettage and postoperative specimens. Normal endometrium of 20 randomly chosen patients was used as a control group.ResultsIn endometrial cancer the expression of CD44 was significantly more intensive than in normal endometrium. In postoperative specimens, the CD44 expression was weaker in serous than in endometrioid cancer. There was no significant correlation between the adhesion molecule expression and clinicopathological features: grade,depth of invasion, cervical involvement, serosal and adnexal involvement, lymph-vascular space involvement, lymph node and distant metastases nor FIGO stage.ConclusionsAn increased expression of CD44 in endometrial cancer suggests its possible role in pathogenesis of this disease, however, it doesn’t seem to be crucial. Different expression of the CD44 in endometrioid and papillary-serous type may reflect different pathogenesis of these types of cancer. No statistically proved relation between the investigated molecule expression and clinicopathological parameters suggests scepticism about its use in diagnostic process of endometrial cancer.

show abstract

“…Aberrant expression of isoforms, such as CD44v3 and CD44v6, is indicative of a loss of splice control in malignant cells and increases the affinity of malignant cells to extracellular matrix ligands such as hyaluronan 4. Data with respect to the immunohistochemically detected expression of CD44v3 and CD44v6 in gynecologic malignancies are inconsistent 5–8…”

mentioning

confidence: 99%

The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma

Hefler

Concin

Mincham

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND Isoforms of the adhesion molecule CD44 are involved in carcinogenesis and the metastatic cascade of tumor cells by increasing the affinity of malignant cells to their extracellular matrix. Preliminary data with respect to the prognostic value of the CD44 isoforms CD44v3 and CD44v6 in patients with vulvar carcinoma showed promising results. The current multicenter study aimed to determine the prognostic value of CD44v3 and CD44v6 in patients with surgically staged vulvar carcinoma. METHODS Expression of CD44v3 and CD44v6 in vulvar carcinoma tissue was assessed by immunohistochemistry. Immunohistochemic staining was performed according to established protocols. Results were correlated to clinical data. RESULTS A positive CD44v3 and CD44v6 staining was detected in 33.3% (33 out of 99) and 39.4% (39 out of 99) of the tumor samples, respectively. Overexpression of CD44v6 was associated with an impaired prognosis with respect to disease‐free survival (P = 0.01) and overall survival (P = 0.04). Multivariate analysis showed that CD44v6 provided prognostic information with respect to disease‐free survival (P = 0.001) and overall survival (P = 0.005) independently of the two established prognosticators, tumor stage and groin lymph node involvement. Overexpression of CD44v3 had no impact on patient survival. CONCLUSIONS The current multicenter study, involving a large series of patients with surgically staged vulvar carcinoma, allowed for multivariate survival analysis and showed that CD44v6 confers prognostic information in addition to that provided by the established clinicopathologic parameters of tumor stage and lymph node status. Cancer 2002;94:125–30. © 2002 American Cancer Society.

show abstract

The prognostic value of CD44 isoform expression in endometrial cancer

Abstract: Summary Isoforms of the transmembrane glycoprotein CD44 have been implicated in tumour cell adhesion, tumour differentiation and metastatic spread in various human malignancies. We investigated the expression of CD44 isoforms containing variant exons v3, v5, v6 and v7-8

Cited by 21 publications

References 19 publications

Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer

Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer

CD44 expression in curettage and postoperative specimens of endometrial cancer

The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma

Contact Info

Product

Resources

About